| 发明名称 | Formulations of histone deacetylase inhibitor and uses therof | ||
| 摘要 | Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described. | ||
| 申请公布号 | US9403032(B2) | 申请公布日期 | 2016.08.02 |
| 申请号 | US201314069233 | 申请日期 | 2013.10.31 |
| 申请人 | Pharmacyclics LLC | 发明人 | Loury David J.;Buggy Joseph J.;Mody Tarak D.;Verner Erik J.;Purro Norbert;Balasubramanian Sriram |
| 分类号 | A61K31/166;A61N5/10;A61K45/00;A61K9/20;A61K9/28;A61K9/48;A61K9/50;A61K31/343;A61K31/35;A61K31/381;A61K31/40;A61K31/47;A61K31/497;A61K31/69;A61K47/02;A61K47/12;A61K31/4184;A61K31/573;A61K31/704;A61K45/06;C07D307/85;A61K38/05 | 主分类号 | A61K31/166 |
| 代理机构 | Foley Hoag LLP | 代理人 | Foley Hoag LLP |
| 主权项 | 1. A method of treating a hematologic cancer selected from: B-cell lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and multiple myeloma in an individual in need thereof, comprising administering to the individual a therapeutically-effective amount of Compound 1or a pharmaceutically-acceptable salt thereof. | ||
| 地址 | Sunnyvale CA US | ||